According to Zhitong Finance App, Spike Health (00314) issued an announcement. On October 29, 2026, Spay Investment (a wholly-owned subsidiary of the Company) (as the seller) and Dashenlin (as the buyer) signed an equity transfer agreement. Spai Investment conditionally agreed to sell all of its shares in the target company Shanghai Zhongzhihe (a wholly-owned subsidiary of the Company) at a total cost of RMB 15 million. After the Shanghai Zhongzhihe sale is completed, the Group will no longer hold any interest in the Target Group, the Target Group will no longer be a subsidiary of the Group, and its assets and liabilities will no longer be included in the Group's consolidated financial statements. Oshanbayashi will indirectly acquire 100% of the shares of the target subsidiary held by the target company.
The Company will conduct strategic reviews of the Group's assets from time to time to enhance shareholder value. The Group has made commercial medical insurance and health management business a development priority since 2024. With strong industry trends and policy support, these business segments showed strong growth momentum, and the gross margin was significantly higher than the specialty pharmacy business. Since the strategic review, the Company has carried out sales in line with Speciality to sell some specialty pharmacies previously operated by the Group and part of the distribution infrastructure surrounding its specialty pharmacy business.
Considering the current market conditions of the pharmacy industry and the current operating performance of the pharmacy business of target companies and target subsidiaries, the board of directors believes that the Shanghai Zhongzhihe sales project can further focus on its core strategy, optimize resource allocation, strengthen financial support for its core business, increase the Group's overall gross profit margin, and accelerate the achievement of the Group's overall profit target. After the completion of the Shanghai Zhongzhihe sale, the Group will no longer operate any specialty pharmacy and will continue to focus on the Group's commercial medical insurance and health management business.